Let's take a look at the executives of worldwide listed companies which participate with Dr. Kim in this meeting:
Dmitry Grishin, Co-founder, CEO & Chairman, Mail Ru Group (Market cap 3 billion $)
and Founder, Grishin Robotics
CFO and CAO, Nexon (Market cap 5 billion $)
Chairman and Managing Director, Biocon (Market cap 57 billion $)
Vice Chairman and CEO, HCL Technologies (Market cap 465 billion $)
John G. Rice
Vice Chairman, General Electric Company (Market cap 236 billion $)
James E. Rogers
Chairman, President and CEO, Duke Energy (Market cap 49 billion $)
Co-Founder, Facebook (Market cap 68 billion $)
Founder and Chairman, Suzlon Group (only Suzlon Energy has a market cap of 44 billion $)
Jay S. Walker
Founder, Priceline (Market cap 35 billion $)
Founder, Tudou (Market cap 3.5 billion $)
Chairman, Microsoft Asia Pacific R&D Group and Corporate Vice President, Microsoft
Now let's see the comment about Dr. Kim in this page:
"J. Joseph Kim
President & CEO, Inovio Pharmaceuticals
Dr. J. Joseph Kim is President & CEO of Inovio Pharmaceuticals, a biotech company that is revolutionizing vaccines with DNA-sequenced vaccines for cancer, HIV, influenza and other infectious diseases.
The Gates Foundation is funding his malaria vaccine, the Director of the National Institutes of Health called his flu vaccine "transformational medicine," and the U.S. NIH granted him $25 million to speed the development of his HIV vaccine.
He earned a BS in Chemical Engineering and Economics from MIT, a PhD in Biochemical Engineering from the University of Pennsylvania, and an MBA in Finance from the Wharton School. Dr. Kim has published more than 100 peer-reviewed scientific papers, holds numerous patents and sits on several editorial boards and review panels."
Question: After reading about the aforementioned participants and their companies, is there anyone who does not understand the significance of Inovio's President and CEO invitation in this meeting, among the executives of well established corporate giants?
I believe it gives a good idea about what high profile experts think about the quality and the prospects of Dr. Kim's and his associates' work in Inovio.
8:50 PM EST. Tuesday Feb 19
Wednesday, February 20, 2013
Almar Latour, Executive Editor, The Wall Street Journal and Dow Jones
Human Imagination On Display: The Early Effort To Understand The Body
Using exhibits from The Library of the Human Imagination, Jay S. Walker looks at man's continuing quest to understand and treat illnesses. View details here.
Saving Lives. Saving Dollars. Can Drug Makers Rise To The Challenge?
Advances in drug developments are allowing people to live longer more satisfying lives. But developing and getting a drug to market remains a time-consuming and costly process, and as a result many new drugs are priced out of the reach of much of the world's population. Can this change?
Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon
Patrick Bergstedt, President, Asia Pacific, MSD
J. Joseph Kim, President and CEO, Inovio Pharmaceuticals
Moderated by Geeta Anand, News Editor, The Wall Street Journal and Dow Jones
I hope you're right. Dr. Kim is only participating in a short panel discussion it looks like, so while the exposure will be great, I'm not sure INO news will matter at this conference.